JP2022500441A5 - - Google Patents

Info

Publication number
JP2022500441A5
JP2022500441A5 JP2021514123A JP2021514123A JP2022500441A5 JP 2022500441 A5 JP2022500441 A5 JP 2022500441A5 JP 2021514123 A JP2021514123 A JP 2021514123A JP 2021514123 A JP2021514123 A JP 2021514123A JP 2022500441 A5 JP2022500441 A5 JP 2022500441A5
Authority
JP
Japan
Prior art keywords
crystal morphology
crystalline form
degrees
diffraction pattern
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500441A (ja
JP7405840B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050771 external-priority patent/WO2020056105A1/en
Publication of JP2022500441A publication Critical patent/JP2022500441A/ja
Publication of JP2022500441A5 publication Critical patent/JP2022500441A5/ja
Application granted granted Critical
Publication of JP7405840B2 publication Critical patent/JP7405840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514123A 2018-09-13 2019-09-12 結晶性(r)-5-カルバモイルピリジン-3-イル-2-メチル-4-(3-(トリフルオロメトキシ)ベンジル)ピペラジン-1-カルボキシレート、組成物、及びその使用方法 Active JP7405840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731014P 2018-09-13 2018-09-13
US62/731,014 2018-09-13
PCT/US2019/050771 WO2020056105A1 (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022500441A JP2022500441A (ja) 2022-01-04
JP2022500441A5 true JP2022500441A5 (cg-RX-API-DMAC7.html) 2022-08-12
JP7405840B2 JP7405840B2 (ja) 2023-12-26

Family

ID=68069873

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514123A Active JP7405840B2 (ja) 2018-09-13 2019-09-12 結晶性(r)-5-カルバモイルピリジン-3-イル-2-メチル-4-(3-(トリフルオロメトキシ)ベンジル)ピペラジン-1-カルボキシレート、組成物、及びその使用方法

Country Status (28)

Country Link
US (4) US11053199B2 (cg-RX-API-DMAC7.html)
EP (3) EP3849970B1 (cg-RX-API-DMAC7.html)
JP (1) JP7405840B2 (cg-RX-API-DMAC7.html)
KR (1) KR102844245B1 (cg-RX-API-DMAC7.html)
CN (3) CN118561814A (cg-RX-API-DMAC7.html)
AU (1) AU2019337623B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004340A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112200A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003295A2 (cg-RX-API-DMAC7.html)
DK (2) DK4434583T5 (cg-RX-API-DMAC7.html)
EA (1) EA202190511A1 (cg-RX-API-DMAC7.html)
ES (2) ES2993173T3 (cg-RX-API-DMAC7.html)
FI (2) FI3849970T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20260757T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068147T2 (cg-RX-API-DMAC7.html)
IL (1) IL281276B2 (cg-RX-API-DMAC7.html)
LT (2) LT3849970T (cg-RX-API-DMAC7.html)
MA (2) MA71839B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002923A (cg-RX-API-DMAC7.html)
MY (2) MY208901A (cg-RX-API-DMAC7.html)
PL (2) PL3849970T3 (cg-RX-API-DMAC7.html)
PT (2) PT4434583T (cg-RX-API-DMAC7.html)
RS (2) RS68181B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102143RA (cg-RX-API-DMAC7.html)
SI (1) SI3849970T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202600252T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020056105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
EP3099332A4 (en) * 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
PT3595665T (pt) * 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022512399A5 (cg-RX-API-DMAC7.html)
JP2023116503A5 (cg-RX-API-DMAC7.html)
JP2024026550A5 (cg-RX-API-DMAC7.html)
JP2022183220A5 (cg-RX-API-DMAC7.html)
JPWO2022138987A5 (cg-RX-API-DMAC7.html)
RU2466129C2 (ru) Твердые формы рацемического илапразола
JP2011513485A5 (cg-RX-API-DMAC7.html)
JP2010514806A5 (cg-RX-API-DMAC7.html)
JP2022543155A5 (cg-RX-API-DMAC7.html)
JP2016537326A5 (cg-RX-API-DMAC7.html)
JP2020521732A5 (cg-RX-API-DMAC7.html)
JP2015516968A5 (cg-RX-API-DMAC7.html)
JP2023528565A (ja) Glp-1受容体アゴニストの結晶形aおよびその調製法
JP2012500819A5 (cg-RX-API-DMAC7.html)
JP2024521412A5 (cg-RX-API-DMAC7.html)
JP2024530164A5 (cg-RX-API-DMAC7.html)
HU228423B1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2024505063A5 (cg-RX-API-DMAC7.html)
WO2018019084A1 (zh) 一种苯甲酰胺类化合物及其在制备抑制癌细胞增殖和/或治疗癌症的药物中的应用
US20210130333A1 (en) Crystal of benzofuran derivative free base and preparation method
JP2017210488A5 (cg-RX-API-DMAC7.html)
CN103724307A (zh) 含笑内酯二甲基胺富马酸盐的晶型及制备方法
WO2023014793A1 (en) Process for polyamide synthesis
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида
CN111386268A (zh) 一种urat1抑制剂的晶型及其制备方法